Monopar Therapeutics (Monopar Therapeutics) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Debt-to-Asset?

Monopar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Monopar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Monopar Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $8.91 Mil. Monopar Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Monopar Therapeutics Debt-to-Asset Historical Data

The historical data trend for Monopar Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Debt-to-Asset Chart

Monopar Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Monopar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Monopar Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Monopar Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monopar Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's Debt-to-Asset falls into.

Monopar Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Monopar Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.345
	=	0.00

Monopar Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	8.912
	=	0.00

Monopar Therapeutics (NAS:MNPR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Monopar Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Monopar Therapeutics (Monopar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

1IY:Germany

Address

1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website

https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Executives

Michael J Brown	director	C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner	director	ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson	director	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto	officer: Chief Financial Officer	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson	director, officer: Chief Executive Officer	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Andrew Cittadine	officer: Chief Operating Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Patrice Rioux	other: Acting Chief Medical Officer	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr	director	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa	officer: Chief Medical Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc	10 percent owner	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson	officer: SVP, Clinical Development	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc	10 percent owner	C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc	10 percent owner	1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091